Cargando…

Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD

Highly contagious respiratory illnesses like influenza and COVID-19 pose serious risks to public health. A two-in-one vaccine would be ideal to avoid multiple vaccinations for these diseases. Here, we generated a chimeric receptor binding domain of the spike protein (S-RBD) and hemagglutinin (HA)-st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yulei, Liu, Peipei, Hao, Tianjiao, Liu, Sheng, Wang, Xi, Xie, Yufeng, Xu, Ke, Lei, Wenwen, Zhang, Cheng, Han, Pu, Li, Ying, Jin, Xiyue, Huan, Yu, Lu, Yafei, Zhang, Rong, Li, Xiaoyan, Zhao, Xin, Xu, Kun, Liao, Pu, Lu, Xuancheng, Bi, Yuhai, Song, Hao, Wu, Guizhen, Zhu, Baoli, Gao, George F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348046/ https://www.ncbi.nlm.nih.gov/pubmed/37394992 http://dx.doi.org/10.1080/22221751.2023.2231573

Ejemplares similares

A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
por: An, Yaling, et al.
Publicado: (2022)

Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
por: Zhang, Ting, et al.
Publicado: (2023)

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants
por: Fan, Feng, et al.
Publicado: (2023)

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
por: Wang, Shixia, et al.
Publicado: (2022)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants
por: Fan, Shengtao, et al.
Publicado: (2022)

Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort
por: Ma, Ensi, et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Aggravated pneumonia and diabetes in SARS-CoV-2 infected diabetic mice
por: Huang, Qing, et al.
Publicado: (2023)

Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing
por: Tong, Renyang, et al.
Publicado: (2023)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

COVID-19: imbalanced cell-mediated immune response drives to immunopathology
por: Wang, Jun, et al.
Publicado: (2022)

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity
por: Zhang, Li, et al.
Publicado: (2022)

Tracking trends in COVID-19 vaccines based on 47 different vaccines: A bibliometric review
por: Tao, Zhongbin, et al.
Publicado: (2023)

Assessment and sero-diagnosis for coronaviruses with risk of human spillover
por: Zheng, Xiao-Shuang, et al.
Publicado: (2023)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Induction of significant neutralizing antibodies against SARS-CoV-2 by a highly attenuated pangolin coronavirus variant with a 104nt deletion at the 3'-UTR
por: Lu, Shanshan, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Comparative global B cell receptor repertoire difference induced by SARS-CoV-2 infection or vaccination via single-cell V(D)J sequencing
por: He, Bing, et al.
Publicado: (2022)

Coronavirus RNA-dependent RNA polymerase interacts with the p50 regulatory subunit of host DNA polymerase delta and plays a synergistic role with RNA helicase in the induction of DNA damage response and cell cycle arrest in the S phase
por: Quan, Li, et al.
Publicado: (2023)

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease
por: Xu, Ke, et al.
Publicado: (2023)

Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines
por: Liu, Zezhong, et al.
Publicado: (2023)

Effectiveness of vaccination in reducing hospitalization and mortality rates in dialysis patients with Omicron infection in China: A single-center study
por: Zhang, Quanchao, et al.
Publicado: (2023)

Safety evaluation of COVID-19 vaccination during early pregnancy: A single-center prospective cohort study of Chinese pregnant women
por: Lu, Ling, et al.
Publicado: (2023)

Reply to the letter to the editor titled “Guillain-Barre / Miller-Fisher overlap syndrome or acute, motor and sensory, axonal neuropathy with cranial nerve involvement?”
por: Liang, Hao, et al.
Publicado: (2023)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
por: Liang, Ziteng, et al.
Publicado: (2023)

Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19
por: Feng, Jia-Lu, et al.
Publicado: (2023)

Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model
por: Chen, Yanxia, et al.
Publicado: (2022)

A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity
por: Li, Yang, et al.
Publicado: (2022)

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
por: Wang, Fengze, et al.
Publicado: (2022)

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
por: Li, Yuzhong, et al.
Publicado: (2021)

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
por: Shen, Yinzhong, et al.
Publicado: (2022)

Reply to the letter on the effects of COVID-19 vaccination on epileptic seizures in patient with epilepsy
por: Yu, Lu
Publicado: (2023)

Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave
por: Lu, Guanzhu, et al.
Publicado: (2022)

Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort
por: Zhu, Liguo, et al.
Publicado: (2023)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2022)

The interplay between emerging human coronavirus infections and autophagy
por: Zhao, Zhenyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m4lsvgo0tvkgc869b3js7ab1p0